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Abstract
Introduction: Iron overload is a major problem in patients with b-thalassemia major, and it has many structural and metabolic conse-
quences. In this study, we aimed to consider the prevalence of endocrine abnormalities in patients with b-thalassemia major and thalas-
semia intermedia.
Materials and methods: We ordered following tests for consideration endocrine abnormalities: fasting plasma glucose, oral glucose 
tolerance, iron, total iron binding capacity, ferritin, thyroid-stimulating hormone (TSH), free thyroxin (fT4), free triiodothyronine (fT3), 
parathyroid hormone levels.
Results: According to our study including 70 patients with thalassemia major, 7 (10%) had diabetes, 5 (7.1%) had impaired glucose tole- 
rance, 9 (12.8%) had hypothyroidism, 2 (2.8%) had hypoparathyroidism, 2 (2.8%) had hyperparathyroidism. Of 22 patients with thalas-
semia intermedia, 1 (4.5%) had diabetes.
Conclusions: These findings reinforce the importance of regular follow-up of patients with b-thalassemia major and thalassemia intermedia 
for early detection and management of associated complications. In this way, the prevalence of endocrine abnormalities can be decreased 
in future. (Endokrynol Pol 2012; 63 (4): 260–263)
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Streszczenie
Wstęp: Przeładowanie żelazem jest częstym problemem u osób chorujących na beta-talasemię major, związanym z wieloma struktural-
nymi i metabolicznymi następstwami. Niniejsze badanie przeprowadzono w celu oceny częstości zaburzeń metabolicznych u pacjentów 
z b-talasemią major i intermedia.
Materiały i metody: Przeprowadzono następujące badania pozwalające ocenić zaburzenia gospodarki hormonalnej: glikemia na czczo, 
doustny test tolerancji glukozy, stężenie żelaza, całkowita zdolność wiązania żelaza, stężenia ferrytyny, tyreotropiny (TSH), wolnej tyrok-
syny (fT4), wolnej trijodotyroniny (fT3) i parathormonu.
Wyniki: Spośród 70 chorych z talasemią major włączonych do niniejszego badania u 7 (10%) osób stwierdzono cukrzycę, u 5 (7,1%) nie-
prawidłową tolerancję glukozy, u 9 (12,8%) niedoczynność tarczycy, a u 2 (2,8%) nadczynność tarczycy. W grupie 22 chorych z talasemią 
intermedia 1 (4,5%) osoba chorowała na cukrzycę.
Wnioski: Uzyskane wyniki potwierdzają znaczenie regularnych badań u chorych na beta-talasemię major i intermedia, co umożliwia 
wczesne wykrycie i rozpoczęcie leczenia związanych z tą chorobą powikłań. Takie postępowanie może się przyczynić do zmniejszenia 
częstości zaburzeń hormonalnych w przyszłości. (Endokrynol Pol 2012; 63 (4): 260–263)
Słowa kluczowe: przeładowanie żelazem, zaburzenia hormonalne, talasemia major, talasemia intermedia
Introduction
Trace elements are necessary for the regular function-
ing of the human body [1]. A deficiency of a trace 
element results in problems with bodily functions 
[2, 3]. Similarly, an excess of a trace element leads to 
important problems. Beta-thalassaemia is a disease 
in which iron overload and iron deposition in tis-
sues is a common and devastating problem if proper 
precautions are not taken. Beta-thalassaemia repre-
sents a group of recessively inherited haemoglobin 
disorders characterised by reduced synthesis of 
b-globulin chain. About 3% of the world’s popula-
tion carries b-thalassaemia genes. The homozygous 
state results in severe anaemia, which needs regular 
blood transfusion. Treatment with transfusion and 
chelating therapy has considerably prolonged sur-
vival in thalassaemic patients [4]. Treatment consists 
of multiple blood transfusions, a complication of 
which is iron overload. At the same time, there has 
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been an increase in the frequency of complications of 
this therapy caused by iron overload [5, 6].
Iron overload has for a long time been considered 
to be the major cause of endocrine abnormalities of 
b-thalassaemia, and this is supported by histological 
studies of different endocrine glands [7–9]. The precise 
mechanism whereby iron overload causes tissue dam-
age is not completely understood, although there is evi-
dence of free radical formation and lipid peroxidation 
resulting in mitochondrial lysosomal damage. In recent 
years, several authors have reported a high incidence 
of endocrine abnormalities in children, adolescents and 
young adults suffering from thalassaemia major [9–11].
In this study, we wanted to consider the prevalence 
of endocrine abnormalities in patients with b-thalassae-
mia major and thalassaemia intermedia.
Material and methods
In thıs study, we evaluated endocrine complications of 
the disease in all b-thalassaemia major and intermedia 
patients aged 11 and above (92 patients) who were 
followed up and treated at the Thalassaemia Centre 
of the Education and Research Hospital, Antalya, 
Turkey. All patients had been maintained on a regular 
transfusion programme (every 15–30 days) with the 
aim of maintaining pre-transfusion haemoglobin lev-
els above 9 g/dL. We ordered the following tests for 
the consideration of endocrine abnormalities: fasting 
plasma glucose, oral glucose tolerance, iron, total iron 
binding capacity, ferritin, thyroid-stimulating hormone 
(TSH), free thyroxin (fT4), free triiodothyronine (fT3), 
and parathyroid hormone levels. Blood glucose, iron, 
and total iron binding capacity (TIBC) were measured 
by photometry assay (Aeroset Abbott Diagnostics). Fer-
ritin, TSH, fT4, fT3 and PTH levels were determined by 
immunoassay (Beckmann Unicel DxI 800). Evidence for 
diabetes mellitus was based on American Diabetes As-
sociation and World Health Organisation criteria. The 
presence of a low fT4 level and a high TSH level was 
accepted as evidence for the existence of primary overt 
hypothyroidism.
SPSS 10.0.1 software was used for statistical analy-
sis. All data are presented as mean ± standard dev- 
iation (SD). The t test was used, setting p < 0.05 for 
significance.
Results
Of 92 patients with b-thalassaemia, 22 (23.9%) had tha-
lassaemia intermedia and 70 (77.1%) had thalassaemia 
major. Of patients with thalassaemia intermedia, 13 
(59.1%) were male and nine (40.9%) were female. Of 
patients with thalassaemia major, 45 (64.2%) were male 
and 25 (35.8%) were female. In all, 58 (63.1%) were male 
and 34 (36.9%) were female.
In patients with thalassaemia intermedia, the 
mean ± SD age was 37.54 ± 11.8 years, the mean ± SD 
glucose level was 87.22 ± 14.25 mg/dL, the mean ± SD 
iron level was 195 ± 29 mg/dL, the mean ± SD TIBC 
level was 235 ± 38 mg/dL, the mean ± SD ferritin 
level was 957 ± 218 ng/mL, the mean ± SD TSH le-
vel was 1.83 ± 0.83 UI/mL, the mean ± SD fT3 level 
was 2.78 ± 0.28 pg/mL, the mean ± SD fT4 level was 
0.73 ± 0.09 pg/mL, and the mean ± SD PTH level was 
47.48 ± 21.07 pg/mL (Table I).
In patients with thalassaemia major, the mean ± SD 
age was 18.66 ± 6.48 years, the mean ± SD glucose 
level was 112.47 ± 71.93 mg/dL, the mean ± SD iron 
level was 235 ± 45 mg/dL, the mean ± SD TIBC level 
was 240 ± 37 mg/dL, the mean ± SD ferritin level 
was 2,350 ± 450 ng/mL, the mean ± SD TSH level 
Table I. Demographic and biochemical characteristics of 22 patients with thalassaemia intermedia
Tabela I. Demograficzna i biochemiczna charakterystyka 22 chorych na talasemię intermedia
Parameters Minimum Maximum Mean ± SD Reference range
Age (years) 11 55 37.54 ± 11.8 –
Glucose [mg/dL] 69 133 87.22 ± 14.25 70–110
TSH [UI/mL] 0.54 3.4 1.83 ± 0.83 0.34–5.6
fT4 [pg/mL] 0.56 0.88 0.73 ± 0.09 0.54–1.12
fT3 [pg/mL] 2.14 3.45 2.78 ± 0.28 2.5–3.9
PTH [pg/mL] 17.8 81.7 47.48 ± 21.07 15–88
Ferritin [ng/mL] 285 1,750 957 ± 218 11–306
Iron [mg/dL] 104 295 195 ± 29 25–156
TIBC [mg/dL] 117 387 235 ± 38 250–450
TSH — thyroid-stimulating hormone; fT4 — free thyroxin; fT3 — free triiodothyronine; PTH — parathyroid hormone; TIBC — total iron binding capacity
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was 4.73 ± 13.45 UI/mL, the mean ± SD fT3 level 
was 2.86 ± 0.38 pg/mL, the mean ± SD fT4 level was 
0.67 ± 0.14 pg/mL, and the mean ± SD PTH level was 
40.8 ± 19.32 pg/mL (Table II).
The age of patients with thalassaemia major was 
significantly low (p < 0.05). The serum ferritin level of 
patients with thalassaemia major was significantly high 
(p < 0.05). The serum PTH level was significantly higher 
in patients with thalassaemia intermedia (p < 0.05). 
There were no significant differences regarding serum 
glucose, iron, TIBC, TSH, fT3, or fT4 levels between pa- 
tients with thalassaemia major and intermedia (p > 0.05).
According to the data, of 70 patients with thalas-
saemia major, seven (10%) had diabetes, nine (12.8%) 
had hypothyroidism, five (7.1%) had impaired glucose 
tolerance, two (2.8%) had hypoparathyroidism, and 
two (2.8%) had hyperparathyroidism. Of 22 patients 
with thalassaemia intermedia, one (4.5%) had diabetes.
Serum iron, iron binding capacity, and ferritin levels 
of patients with diabetes and hypothyroidism were not 
significantly different from those patients who had no 
diabetes and hypothyroidism (p > 0.05).
Discussion
Endocrine and metabolic abnormalities are quite com-
mon in patients with b-thalassaemia. Abnormal glucose 
tolerance is an important endocrine abnormality in 
these patients. Glucose intolerance usually develops in 
adolescence, even though baseline blood glucose levels 
are frequently normal. Diabetes mellitus later in life is 
also a frequent complication, mainly due to iron over-
load, chronic liver disease and genetic predisposition.
The prevalence of diabetes has been reported as 
ranging from 2.3% to 24.1% in b-thalassaemia [12, 13]. 
We found that the prevalence of impaired glucose toler-
ance was 7.1% and diabetes was 10% in patients with 
b-thalassaemia major. The prevalance of diabetes was 
4.5% in patients withb-thalassaemia intermedia. Ethnic 
variations are frequently reported in the prevalance and 
complications of diabetes mellitus in these patients. Ong 
et al. reported a prevalance of 8% diabetes mellitus in 
Malay and Chinese patients [14]. Najafipour et al. found 
that prevalance of impaired glucose tolerance was 7.1% 
and diabetes was 8.9% in Iran [9]. Jaruratanasirikul et 
al. reported prevalence of impaired glucose metabolism 
of 12.5% in patients in Thailand [15].
Although the early literature suggested that the 
high prevalence of diabetes mellitus in patients with 
thalassaemia was due to direct impairment of insulin 
excretory function by chronic iron overload [16], Monge 
et al. demonstrated evidence of immune system activa-
tion against pancreatic b-cells in b-thalassaemia patients 
[17]. They proposed that pancreatic iron deposition may 
contribute to selective b-cell damage [18].
Iron overload causes deposition of iron in the thyroid 
gland, with consequent fibrosis of the glandular parenchy-
ma, and progressive thyroid dysfunction going through 
different degrees of severity up to overt hypothyroidism 
[6]. Thyroid dysfunction is known to occur frequently 
in thalassaemia major, but its prevelance and severity 
varies in different cohorts, and long-term natural history 
is poorly understood. In our study, we found that 12.8% 
had hypothyroidism. Zervas et al. reported that 4% had 
hypothyroidism, and 12.5% had subclinical hypothyroi- 
dism [19]. Karamifar et al. showed that 6% of patients had 
hypothyroidism [20]. De Sanctis et al. reported that 21.6% 
were discharged with a diagnosis of hypothyroidism of 
different degrees of severity [21].
Gamberini et al. studied 273 patients with thalas-
saemia major followed from diagnosis in the Ferrara 
Centre and divided into three cohorts according to the 
Table II. Demographic and biochemical characteristics of 70 patients with thalassaemia major
Tabela II. Demograficzna i biochemiczna charakterystyka 70 chorych na talasemię major
Parameters Minimum Maximum Mean ± SD Reference range
Age (years) 10 34 18.66 ± 6.48 –
Glucose [mg/dL] 66 510 112.47 ± 71.93 70–110
TSH [UI/mL] 0.04 100 4.73 ± 13.45 0.34–5.6
fT4 [pg/mL] 0.56 0.88 0.67 ± 0.14 0.54–1.12
fT3 [pg/mL] 1.47 3.66 2.86 ± 0.38 2.5–3.9
PTH [pg/mL] 2 95.4 40.8 ± 19.32 15–88
Ferritin [ng/mL] 930 4,500 2,350 ± 450 11–306
Iron [mg/dL] 95 590 235 ± 45 25–156
TIBC [mg/dL] 114 478 240 ± 37 250–450
TSH — thyroid-stimulating hormone; fT4 — free thyroxin; fT3 — free triiodothyronine; PTH — parathyroid hormone; TIBC — total iron binding capacity
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year of their birth. Over time, the prevalence of hypo-
thyroidism, diabetes mellitus and hypoparathyroidism 
increased to 24.4%, 14.7%, and 6.7%, respectively, at 
the time of the study. Incidences peaked in the early 
1980s, and declined in the following years (primary 
hypothyroidism from 6.5% in 1981 to 0.9% in 2007; DM 
from 3.9% in 1986 to 0.8% in 2007; hypoparathyroidism 
from 2.4% in 1984 to 0% in 2007 and correlated with 
the decrease in annual mean serum ferritin levels in all 
patients. The main risk factors associated with endocrine 
complications were high serum ferritin levels, poor 
compliance with desferioxamine (DFO) therapy, early 
onset of transfusion therapy (only for hypogonadism) 
and splenectomy (only for hypothyroidism). Serum 
ferritin levels of approximately 2,000 ng/mL were found 
to correlate with hypogonadism, and 3,000 ng/mL for 
hypothyroidism, hypoparathyroidism and DM. They 
showed that in the last 30 years in the Ferrara Centre the 
incidences of hypothyroidism, diabetes mellitus, and 
hypoparathyroidism declined, and pubertal develop-
ment in males with thalassaemia major improved in 
patients on DFO treatment born after 1976. The efficacy 
of alternative chelation regimens with deferiprone or 
deferasirox to monotherapy with desferioxamine re-
mains to be established [22].
These findings reinforce the importance of the 
regular follow-up of patients with b-thalassaemia major 
and thalassaemia intermedia for early detection and 
management of associated complications. In this way, 
the future prevalence of endocrine abnormalities can 
be lessened.
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